{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:34:00Z","timestamp":1760146440137,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Lyell\u2019s syndrome or Toxic Epidermal Necrolysis (TEN) is a rare and life-threatening dermatological disease. Most commonly, this syndrome is drug-induced, and is a result of an immune-allergic reaction to medications. Anti-cancer drugs were not the most frequent groups of therapeutic agents related to Lyell\u2019s syndrome, but the emergence of new therapeutic classes, particularly targeted therapy and immunotherapy, is changing current data. We present two cases of Lyell\u2019s syndrome induced by anticancer drugs. (1) TEN in a man treated for metastatic urothelial carcinoma with Enfortumab Vedotin. (2) TEN in a man with metastatic melanoma treated with Nivolumab and Ipilimumab. Despite quick medical treatment and transfer to a severe burn unit, both patients died of TEN.<\/jats:p>","DOI":"10.3390\/curroncol31110509","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:36:39Z","timestamp":1730806599000},"page":"6891-6897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Cancer Drug-Induced Lyell\u2019s Syndrome: A Series of Two Patients"],"prefix":"10.3390","volume":"31","author":[{"given":"Julie","family":"Coussirou","sequence":"first","affiliation":[{"name":"Institut du Cancer Avignon Provence, 250 Chemin de Baigne-Pieds, 84000 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Ravoire","sequence":"additional","affiliation":[{"name":"Institut du Cancer Avignon Provence, 250 Chemin de Baigne-Pieds, 84000 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Stancu","sequence":"additional","affiliation":[{"name":"Institut du Cancer Avignon Provence, 250 Chemin de Baigne-Pieds, 84000 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5893-316X","authenticated-orcid":false,"given":"L\u00e9a","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Institut du Cancer Avignon Provence, 250 Chemin de Baigne-Pieds, 84000 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/TME.0000000000000225","article-title":"A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"41","author":"Woolum","year":"2019","journal-title":"Adv. Emerg. Nurs. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights from a Pan-European Multicenter Study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen","year":"2014","journal-title":"Anticancer Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1200\/EDBK_281107","article-title":"The resurgence of antibody drug conjugates in cancer therapeutics: Novel targets and payloads","volume":"40","author":"Boni","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zimmerman, D., and Dang, N.H. (2020). Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Immunologic reactions. Oncologic Critical Care, Springer.","DOI":"10.1007\/978-3-319-74588-6_195"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2147\/DDDT.S168248","article-title":"A case report of toxic epidermal necrolysis associated with AZD-9291","volume":"12","author":"Wang","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, H., Ma, Q., Sun, Y., Zhang, K., Xing, Y., and Li, H. (2022). Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1065137"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ccr3.3695","article-title":"Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer","volume":"9","author":"Koshizuka","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2020.10.020","article-title":"A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis","volume":"7","author":"Francis","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7524726","DOI":"10.1155\/2020\/7524726","article-title":"Toxic epidermal necrolysis (TEN)\/Stevens-Johnson Syndrome (SJS) epidemiology and mortality rate at King Fahad Specialist Hospital (KFSH) in Qassim Region of Saudi Arabia: A retrospective study","volume":"2020","author":"Alajaji","year":"2020","journal-title":"Dermatol. Res. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, L., Varghese, S., Bassir, F., Lo, Y.C., Ortega, C.A., Shah, S., Blumenthal, K.G., Phillips, E.J., and Zhou, L. (2022). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A systematic review of PubMed\/MEDLINE case reports from 1980 to 2020. Front. Med., 9.","DOI":"10.3389\/fmed.2022.949520"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","first-page":"651590","article-title":"Toxic epidermal necrolysis and graft-versus-Host reaction: Revisiting a puzzling similarity","volume":"2013","author":"Paquet","year":"2013","journal-title":"ISRN Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12821","DOI":"10.1111\/sji.12821","article-title":"Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer","volume":"90","author":"Bakacs","year":"2019","journal-title":"Scand. J. Immunol."},{"key":"ref_24","unstructured":"Witjes, J.A., Bruins, H.M., Cathomas, R., Comp\u00e9rat, E.M., Cowan, N.C., Gakis, G., Hern\u00e1ndez, V., Linares Espin\u00f3s, E., Lorch, A., and Neuzillet, Y. (2020). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer, European Association of Urology (EAU)."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.2147\/CMAR.S224223","article-title":"Emerging treatment options for the treatment of metastatic urothelial cancer: Therapeutic potential of enfortumab vedotin","volume":"20","author":"Jain","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2021.1929168","article-title":"Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma","volume":"21","author":"Wong","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Fouchard","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN)","volume":"158","author":"Koh","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"ljae321","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress of Stevens-Johnson syndrome\/toxic epidermal necrolysis: Diagnosis criteria, pathogenesis and therapy","volume":"2024","author":"Hama","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chen, P.Y., Li, Z.Y., and Cai, S.Q. (2023). Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1188523"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Li, X., Li, G., Chen, D., Su, L., Wang, R.P., and Zhou, Y. (2023). Case Report: Sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.912168"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12672-023-00749-5","article-title":"Case report: A successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies","volume":"14","author":"Li","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_36","first-page":"e41439","article-title":"Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient with Metastatic Non-small Cell Lung Cancer: A Case Report","volume":"15","author":"Sandhu","year":"2023","journal-title":"Cureus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3000605231173556","DOI":"10.1177\/03000605231173556","article-title":"A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma","volume":"51","author":"Gong","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/iju5.12562","article-title":"Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma","volume":"6","author":"Mimura","year":"2022","journal-title":"IJU Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.14740\/jmc3992","article-title":"Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient with Metastatic Gastric Adenocarcinoma","volume":"13","author":"Saad","year":"2022","journal-title":"J. Med. Cases"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:13Z","timestamp":1760113573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["curroncol31110509"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31110509","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,11,4]]}}}